LAKE FOREST, Ill., April 8, 2026
Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by Garda Therapeutics in an all-cash transaction valued at approximately $125.1 million, representing a significant consolidation move within the pharmaceutical sector. The deal includes $18 per share in cash plus contingent value rights (CVRs) tied to future product milestones, offering shareholders a premium and structured upside potential.
Strategic Acquisition Drives Portfolio Optimization
The acquisition follows a comprehensive strategic review process initiated by Assertio in early 2025, during which the company evaluated multiple options including mergers, asset monetization, and standalone growth. After engaging with over 35 potential counterparties, the board determined that the transaction with Garda provides the best value realization for shareholders in a dynamic and evolving pharmaceutical market.
As part of the broader transaction, Assertio has also divested its non-core product portfolio to Cosette Pharmaceuticals, including assets such as Indocin®, Sympazan®, and Cambia®. This restructuring allows the company to streamline its focus while maximizing overall transaction value. The deal structure reflects a strategic shift toward focused asset management and operational efficiency, a growing trend in the pharmaceutical industry.
The transaction represents a 34.6% premium to Assertio’s unaffected stock price and up to 62.2% premium to its 60-day volume-weighted average price, underscoring the attractiveness of the offer and the value of its commercial drug portfolio.
Advertisement
Transaction Structure and Regulatory Pathway
Under the terms of the agreement, Garda will initiate a tender offer to acquire all outstanding shares of Assertio, followed by a second-step merger to complete the acquisition. The transaction is expected to close in the second quarter of 2026, subject to customary conditions, including shareholder participation in the tender offer.
Notably, the deal is not expected to require significant regulatory approvals, enabling a streamlined execution timeline. Upon completion, Assertio will become a wholly owned subsidiary of Garda, and its shares will be delisted from Nasdaq, marking a transition to private ownership.
The inclusion of contingent value rights linked to Sprix® milestones provides additional potential upside for shareholders, aligning incentives with future product performance. This structure highlights the increasing use of innovative financial mechanisms in pharmaceutical M&A transactions to balance risk and reward.
Implications for Pharma Industry and Market Dynamics
The acquisition reflects broader trends in the pharmaceutical industry, where companies are pursuing strategic consolidation and portfolio realignment to remain competitive in a rapidly evolving regulatory and commercial environment. By acquiring Assertio, Garda gains access to a portfolio of differentiated pharmaceutical products and established commercial capabilities, strengthening its position in key therapeutic areas.
For Assertio, the transaction provides a clear path to value realization amid ongoing market pressures, including changing reimbursement landscapes and macroeconomic challenges. The deal also demonstrates the importance of strategic agility and proactive decision-making in navigating the complexities of the pharmaceutical sector.
Additionally, the integration of operations and assets will require careful management of quality systems, supply chains, and regulatory responsibilities, ensuring continuity of product availability and compliance with global standards. Such transitions are critical in maintaining patient safety and product integrity, key pillars of the cGxP framework.
The agreement between Garda Therapeutics and Assertio Holdings represents a significant milestone in pharmaceutical M&A activity, combining strategic asset optimization with shareholder value creation. With its structured deal terms, premium valuation, and streamlined execution, the transaction highlights the growing importance of consolidation and innovation in shaping the future of the pharmaceutical industry.
Source: Assertio, Garda Therapeutics press release
